The AACR GENIE BioPharma Collaborative (BPC) is a pre-competitive initiative that strategically curates high-quality oncology datasets to support drug development. BPC is structured into distinct phases, each designed to address evolving industry needs. 

BPC Phase 1 and 2: Expanding Solid Tumor Cohort 

• 10 solid cancer cohorts with deep clinical annotation (~20,000 cases). 
• Cohorts aligned with active drug development pipelines. 
• Informs biomarker discovery, clinical development, and regulatory strategy. 

Opportunity: Industry partners can still join Phase 2 with full two-year data embargo intact for advanced access to high-quality cohorts to support ongoing clinical development programs. 

BPC Phase 3: Next Generation Data Expansion 

Building on the success of Phase 2, BPC Phase 3 introduces key enhancements:  

• Expanded solid cancer cohorts – Increased size and representation. 
• Hematological malignancies – New cancer types for broader clinical application. 
• Digital pathology – Integration of whole slide imaging (WSI) data to support emerging AI-driven image analysis . 
• Data refresh cycles – Ensuring contemporaneous, high-fidelity clinico-genomic data. 

Total Cases in BPC Phase 3: ~43,500 

Opportunity: Industry partners are invited to participate in Phase 3, an enhanced offering with a scheduled launch in FY 2026. GENIE is currently solidifying participation through Q3 2025, at which time a formal request will be issued to confirm involvement.